Clinical Trials Logo

Clinical Trial Summary

Fungal infections have increased over the last two decades, largely because of the increasing size of the population at risk, including patients who are immunocompromised, broad-spectrum antibiotics and intravascular catheter users. Essential oils and other extracts of plants have evoked interest as sources of natural products. They have been shown to possess antibacterial, antifungal, antiviral, insecticidal and antioxidant properties. To the best of our knowledge, no study has examined the efficacy of cumin seed extract on relieving vulvovaginal candidiasis in vivo.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03005353
Study type Interventional
Source Assiut University
Status Completed
Phase Phase 2/Phase 3
Start date March 1, 2018
Completion date January 31, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04961593 - PK/PD of Caspofungin in Children Severe Infection
Recruiting NCT01904188 - Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
Recruiting NCT03230058 - Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis Phase 2/Phase 3
Recruiting NCT04287504 - Point-of-care Tests for Bacterial Vaginosis and Candidosis
Recruiting NCT03674359 - Dosage of Plasma 1, 3-β-D-glucan for the Diagnosis of Candidemia.